• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Krystal Biotech Inc. (Amendment)

    2/14/24 4:26:22 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KRYS alert in real time by email
    SC 13G/A 1 tm245846d6_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)

     

    Krystal Biotech, Inc.

    (Name of Issuer)

     

    Common Stock, $0.00001 par value

    (Title of Class of Securities)

     

    501147102 

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x            Rule 13d-1(b)

     

    o            Rule 13d-1(c)

     

    o            Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       

     

     

    CUSIP No. 501147102

     

    1

    Name of Reporting Person

     

    Redmile Group, LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    Delaware

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    1,733,189 (1)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    1,733,189 (1)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,733,189 (1)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    6.1%(2)

    12

    Type of Reporting Person (See Instructions)

     

    IA, OO

     

     

    (1) Redmile Group, LLC’s beneficial ownership of the Issuer’s common stock (“Common Stock”) is comprised of 1,733,189 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (2) Percentage based on 28,206,330 shares of Common Stock outstanding as of October 30, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 6, 2023 (the “Form 10-Q”).

     

       

     

     

    CUSIP No. 501147102

     

    1

    Name of Reporting Person

     

    Jeremy C. Green

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3 SEC Use Only

    4

    Citizenship or Place of Organization

     

    United Kingdom

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    1,733,189 (3)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    1,733,189 (3) 

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,733,189 (3)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    6.1%(4)

    12

    Type of Reporting Person (See Instructions)

     

    IN, HC

     

     

    (3) Jeremy C. Green’s beneficial ownership of Common Stock is comprised of 1,733,189 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (4) Percentage based on 28,206,330 shares of Common Stock outstanding as of October 30, 2023, as reported by the Issuer in the Form 10-Q.

     

       

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Krystal Biotech, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    2100 Wharton Street, Suite 701

    Pittsburgh, Pennsylvania 15203

     

    Item 2.

     

    (a)Names of Persons Filing

     

    Redmile Group, LLC
    Jeremy C. Green

     

    (b)Address of Principal Business office or, if None, Residence

     

    Redmile Group, LLC
     One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    Jeremy C. Green
    c/o Redmile Group, LLC (NY Office)
    45 W. 27th Street, Floor 11
    New York, NY 10001

     

    (c)Citizenship

     

    Redmile Group, LLC: Delaware
    Jeremy C. Green: United Kingdom

     

    (d)Title of Class of Securities

     

    Common Stock, $0.00001 par value

     

    (e)CUSIP Number

     

    501147102

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

       

     

     

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e)x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g)x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Redmile Group, LLC – 1,733,189*
    Jeremy C. Green – 1,733,189*

     

    (b)Percent of class:

     

    Redmile Group, LLC – 6.1%**
    Jeremy C. Green – 6.1%**

     

    (c)Number of shares as to which Redmile Group, LLC has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    1,733,189*

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    1,733,189*

     

    Number of shares as to which Jeremy C. Green has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

       

     

     

    (ii)Shared power to vote or to direct the vote:

     

    1,733,189*

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    1,733,189*

     

    *Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of the Issuer’s Common Stock is comprised of 1,733,189 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    **Percentage based on 28,206,330 shares of Common Stock outstanding as of October 30, 2023, as reported by the Issuer in the Form 10-Q.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See the response to Item 4.

     

    Item 8.Identification and Classification of Members of the Group.

     

    N/A.

     

    Item 9.Notice of Dissolution of Group.

     

    N/A.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

       

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

      Redmile Group, LLC
         
      By: /s/ Jeremy C. Green
       

    Name:

    Jeremy C. Green

        Title: Managing Member

     

        /s/ Jeremy C. Green
       

    Jeremy C. Green

     

       

     

    Get the next $KRYS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRYS

    DatePrice TargetRatingAnalyst
    3/5/2025$245.00Buy
    Jefferies
    8/6/2024$195.00 → $204.00Buy → Neutral
    Citigroup
    11/20/2023$160.00Buy
    Goldman
    10/24/2023$100.00Overweight
    Cantor Fitzgerald
    10/12/2023$160.00Buy
    Citigroup
    9/7/2023$154.00Buy
    Berenberg
    4/18/2023$102.00Buy
    Stifel
    2/28/2023$79.00 → $124.00Neutral → Buy
    Goldman
    More analyst ratings

    $KRYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Krystal Biotech with a new price target

      Jefferies initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $245.00

      3/5/25 7:35:58 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech downgraded by Citigroup with a new price target

      Citigroup downgraded Krystal Biotech from Buy to Neutral and set a new price target of $204.00 from $195.00 previously

      8/6/24 8:53:09 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Krystal Biotech with a new price target

      Goldman initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $160.00

      11/20/23 7:47:05 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    SEC Filings

    See more
    • Krystal Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Krystal Biotech, Inc. (0001711279) (Filer)

      6/2/25 5:12:19 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Krystal Biotech, Inc. (0001711279) (Filer)

      5/19/25 5:06:24 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Krystal Biotech, Inc. (0001711279) (Filer)

      5/6/25 8:09:31 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference

      PITTSBURGH, June 03, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:00 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 2:00 pm ET on Tuesday, June 10, 2025 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biot

      6/3/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

      PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 11:20 am PT on Wednesday, May 14, 2025 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biotechnology co

      5/7/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Announces First Quarter 2025 Financial and Operating Results

      VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis Upcoming clinical readouts in 2025 - CF, AATD, ocular complications of DEB, and aesthetics Strong balance sheet, ending the quarter with $765.3 million in cash and investments PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the first quarter ending March 31, 2025 and provided a business update. "We were thrilled to receive VYJUVEK approval in Europe, and with the p

      5/6/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

      For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a

      5/19/23 1:48:20 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care